Advertisement
U.S. markets close in 5 hours 24 minutes

Mainz Biomed N.V. (4TO.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
0.9530+0.0500 (+5.54%)
As of 02:42PM CET. Market open.

Mainz Biomed N.V.

Robert Koch Strasse 50
Mainz 55129
Germany
49 6131 554 2860
https://mainzbiomed.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees58

Key Executives

NameTitlePayExercisedYear Born
Mr. Guido BaechlerCEO & DirectorN/AN/A1965
Mr. William J. CaragolChief Financial OfficerN/AN/A1967
Dr. Chris Von Torne P.M.P., Ph.D.Chief Operating OfficerN/AN/AN/A
Dr. Frank Krieg-SchneiderChief Technology OfficerN/AN/AN/A
Dr. Moritz Eidens Ph.D.Chief Science Officer & DirectorN/AN/A1984
Stefan ErlachHead of Human ResourcesN/AN/AN/A
Mr. Philipp FreeseC.B.O.N/AN/A1983
Mr. Darin S. LeighChief Commercial OfficerN/AN/A1968
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.

Corporate Governance

Mainz Biomed N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.